Golden
Sangamo Therapeutics

Sangamo Therapeutics

A biotechnology that specializes in genome editing, gene therapy, cell therapy and gene regulation.

Sangamo Therapeutics is a biotechnology company developing gene and cell therapies using genetic engineering that is headquartered in Richmond, California and founded in 1995 by Edward Lanphier.



Sangamo uses zinc finger nuclease technology. In 2005 Sangamo researchers used their technology to target and correct a gene mutation in human cells in culture. In 2009 scientists at Sangamo conducted clinical trials with gene edited T cells for treatment of HIV. In 2018, they initiated the first ever in vivo genome editing clinical trials. . Using their system, zinc finger nucleases were used to insert a healthy version of the IDS gene, which codes for an enzyme called iduronate-2-sulfatase, into liver cells of patients with Hunter syndrome who have mutations that disable the enzyme. While zinc finger gene editing has been performed in cells removed from the body and infused back into the donor, this was the first to directly edit a gene in the body. 

Funding

Grant

On February 7, 2018 Sangamo Therapeutics received a grant worth $11 million from the National Institutes of Health (NIH). 



Timeline

People

Name
Role
LinkedIn

Stephane Boissel

Executive Vice President Corporate Strategies



Heather Turner, JD

Senior Vice President and General Counsel



Sandy Macrae, M.B., Ch.B., Ph.D

CEO



Further reading

Title
Author
Link
Type
Date

AP Exclusive: US scientists try 1st gene editing in the body

Marilynn Marchione

Web



Man 'cured' of HIV through gene editing holds hope for others

Associated Press

Web



Documentaries, videos and podcasts

Title
Date
Link





Companies

Company
CEO
Location
Products/Services

TxCell







References